Exemestane in the Adjuvant Treatment of Breast Cancer in Postmenopausal Women

被引：17

作者：

Kittaneh, Muaiad ^{[1
]}

Gluck, Stefan ^{[1
]}

机构：

[1] Univ Miami, Leonard M Miller Sch Med, 1475 NW 12th Ave,Suite 3310, Miami, FL 33146 USA

来源：

BREAST CANCER-BASIC AND CLINICAL RESEARCH | 2011年 / 5卷

关键词：

aromatase inhibitor; breast cancer; exemestane; disease-free survival; tamoxifen;

D O I：

10.4137/BCBCR.S6234

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Exemestane is an irreversible inhibitor of the aromatase enzyme, which is a key component in the production of estrogen. The majority of breast cancers are sensitive to the proliferative effects of estrogen. Exemestane is approved for the adjuvant treatment of postmenopausal women with breast cancer after 2 to 3 years of tamoxifen therapy, based on a 32% improvement in disease-free survival compared with 5 years of tamoxifen alone (P < 0.001). Exemestane has also shown clinical benefits as an upfront therapy. The safety profile of exemestane shares some side effects with tamoxifen (hot flashes and arthralgia), but is not associated with an increased risk of endometrial cancer or thromboembolic events. This review will discuss in detail the efficacy and safety of exemestane in early breast cancer.

引用

页码：209 / 226

页数：18

共 50 条

[11] Exemestane in postmenopausal women with early or advanced breast cancer: a review
Bertelli, Gianfilippo
Gangadhara, Sharath
EXPERT OPINION ON PHARMACOTHERAPY, 2010, 11 (11) : 1933 - 1942
[12] Exemestane A Review of its Use in Postmenopausal Women with Breast Cancer
Deeks, Emma D.
Scott, Lesley J.
DRUGS, 2009, 69 (07) : 889 - 918
[13] The Effect of Tamoxifen or Exemestane on Bone Mineral Density During the First 2 Years of Adjuvant Treatment of Postmenopausal Women with Early Breast Cancer
Jones, Stephen
Stokoe, Christopher
Sborov, Mark
Braun, Marcus
Ethirajan, Sukumar
Kutteh, Leila
Pippen, John
Patel, Mrugesh
Paul, Devchand
Blum, Joanne L.
Holmes, Frankie Ann
Myron, Mark C.
Cantrell, James
Hartung, Nichole L.
Look, Regan M.
Di Salle, Enrico
Davis, Jennifer C.
Ilegbodu, Des
Asmar, Lina
CLINICAL BREAST CANCER, 2008, 8 (06) : 527 - 532
[14] The effects on lipid serum levels of a 2-year adjuvant treatment with exemestane after tamoxifen in postmenopausal women with early breast cancer
Montagnani, A.
Gonnelli, S.
Cadirni, A.
Caffarelli, C.
Del Santo, K.
Pieropan, C.
Campagna, M. S.
Montomoli, M.
Petrioli, R.
Nuti, R.
EUROPEAN JOURNAL OF INTERNAL MEDICINE, 2008, 19 (08) : 592 - 597
[15] The effect of tamoxifen or exemestane on bone mineral density after 2 years of adjuvant treatment of postmenopausal women with early breast cancer.
Asmar, L.
Negron, A.
Stokoe, C.
Sborov, M.
Braun, M.
Ethirajan, S.
Patel, M.
Davis, J.
Ilegbodu, D.
Jones, S.
BREAST CANCER RESEARCH AND TREATMENT, 2006, 100 : S115 - S115
[16] Exemestane after tamoxifen as adjuvant hormonal therapy in postmenopausal women with breast cancer: effects on body composition and lipids
Francini, G.
Petrioli, R.
Montagnani, A.
Cadirni, A.
Campagna, S.
Francini, E.
Gonnelli, S.
BRITISH JOURNAL OF CANCER, 2006, 95 (02) : 153 - 158
[17] Exemestane after tamoxifen as adjuvant hormonal therapy in postmenopausal women with breast cancer: effects on body composition and lipids
G Francini
R Petrioli
A Montagnani
A Cadirni
S Campagna
E Francini
S Gonnelli
British Journal of Cancer, 2006, 95 : 153 - 158
[18] Pharmacokinetic and pharmacodynamic interaction of adjuvant tamoxifen and exemestane in postmenopausal women treated for early stage breast cancer.
Hutson, PR
Love, RR
Cleary, JF
Kim, K
BREAST CANCER RESEARCH AND TREATMENT, 2002, 76 : S74 - S74
[19] The place of exemestane in the treatment of advanced breast cancer in postmenopausal patients
Lacko, Aleksandra
Duchnowska, Renata
ONCOLOGY IN CLINICAL PRACTICE, 2012, 8 (06): : 246 - 251
[20] Exemestane - A review of its use in postmenopausal women with advanced breast cancer
Clemett, D
Lamb, HM
DRUGS, 2000, 59 (06) : 1279 - 1296

← 1 2 3 4 5 →